

## STABILITY OF CYANOCOBALAMIN SOLUTIONS IN SUNLIGHT AND ARTIFICIAL LIGHT

**IQBAL AHMAD AND WAHID HUSSAIN**

Department of Pharmaceutical Chemistry, Faculty of Pharmacy,  
University of Karachi, Karachi-75270, Pakistan.

### ABSTRACT

A comparison of the degradation of cyanocobalamin (vitamin B<sub>12</sub>) solutions on exposure to sunlight and artificial light has been made using two concentrations, i.e., 950 µg/ml (corresponding to parenteral solutions) and 95 µg/ml (1:10 dilution) at pH 4.0, 5.5 and 7.0. Cyanocobalamin and the photoproduct, hydroxocobalamin (vitamin B<sub>12b</sub>), have been determined by a two component spectrophotometric method at 550 and 525 nm. Cyanocobalamin loss (950 µg/ml and 95 µg/ml) on exposure to sunlight for 2 hours amounts to 14.7-21.0% and 56.3-81.5% respectively indicating that light intensity is the rate determining factor in the reaction. In artificial light for 2 hours B<sub>12</sub> (950 µg/ml and 95 µg/ml) loses 2.7-19.4% and 15-27.7% respectively. Thus B<sub>12</sub> degradation in sunlight is greater compared to that of the artificial light, with the formation of some oxidation products, in addition to B<sub>12b</sub>.

### INTRODUCTION

Cyanocobalamin (vitamin B<sub>12</sub>) on exposure to daylight (Veer *et al.*, 1950; Baxter *et al.*, 1953), sunlight (Baxter *et al.*, 1953; DeMerre and Wilson, 1956), and artificial light (Hogenkamp, 1975; Vogler *et al.*, 1976) is degraded to hydroxocobalamin (vitamin B<sub>12b</sub>) in weak acid solutions as indicated by the spectral variations of degraded solutions (Bayer, 1964; Ahmad *et al.*, 1992). The magnitude of the photochemical change depends upon the intensity and wavelength of light (Anderson *et al.*, 1991). The stability (Hashmi, 1973; DeRitter, 1982; Connors *et al.*, 1986) and photochemistry (Pratt, 1972; Brown, 1973; Kirschbaum, 1981) of cyanocobalamin and derivatives have been reviewed in detail.

Recently some studies on the photolysis of cyanocobalamin alone (Ahmad *et al.*, 1992), in the presence of riboflavin (Ahmad and Hussain, 1992), and its stability in parenteral solutions (Ahmad and Hussain, 1993) have been reported. The present work deals with a study of the degradation of cyanocobalamin in presence of sunlight and artificial light in concentrations employed for parenteral solutions.

### MATERIALS AND METHODS

Cyanocobalamin and hydroxocobalamin (Eur. P.) were obtained from Fluka (Switzerland) and their purity was confirmed by thin layer chromatography (TLC). All solvent and reagents were analytical grade or of the purest form available from BDH/Merck. Citric acid-disodium hydrogen phosphate, pH 4.0-7.0 (ionic strength 0.05 M) was employed as buffer system.

### Photolysis

950 µg/ml and 95 µg/ml of cyanocobalamin were dissolved in the appropriate buffer solution (pH 4.0, 5.5 and 7.0) in a 100 ml volumetric flask (pyrex) and exposed directly to sunlight and to artificial light using Philips HPLN 125 W high pressure mercury vapour fluorescent lamp (emission at 405, 436, 454 and 577 nm) fixed at a distance of 30 cm in a radiation chamber.

### Assay

The concentrations of cyanocobalamin and hydroxocobalamin in photolysed solutions were determined by a two-component spectrophotometric method at 550 and 525 nm (Ahmad et al, 1992).

## RESULTS AND DISCUSSION

Cyanocobalamin is a photosensitive compound and is converted to hydroxocobalamin in aqueous solution under the influence of light (Ahmad *et al*, 1992). In order to study the photostability of cyanocobalamin, B<sub>12</sub> solutions were exposed to sunlight and to artificial light at pH 4.0, 5.5 and 7.0 (pH requirements of B<sub>12</sub> injections 3.8- 7.0; BP, 1988; USP, 1990) and B<sub>12</sub> and B<sub>12b</sub>, content of the degraded solutions was determined.

Cyanocobalamin solutions [950 µg/ml ( $7.0 \times 10^{-4}$  M) and 95 µg/ml ( $7.0 \times 10^{-5}$  M)] at pH 4.0, 5.5 and 7.0 on exposure to sunlight (emission at 295-899 nm) degrade 21.0, 15.8, 14.7% and 81.5, 69.2, 56.3% respectively. The formation of hydroxocobalamin for the two solutions at these pH values was 15.2, 8.9, 8.7% and 78.9, 67.9; 55.2% respectively and the formation of irreversible oxidation products under the same conditions was 5.8, 6.9, 6.0% and 2.6, 1.3, 1.1% respectively (Table 1). The formation of the oxidation products was evident from slight fading of the B<sub>12</sub> solutions and appears to take place through BIM. Exposure of B<sub>12e</sub> solutions (950 µg/ml and 95 µg/ml) at pH 4.0 to sunlight for two hours resulted in a loss amounting to 22.5 and 18.7%, with the solutions turning yellowish red and yellowish pink respectively.

Under the artificial light B<sub>12</sub> solutions at the two concentrations at pH 4.0, 5.5 and 7.0 lose 19.4, 3.5, 1.5% and 27.7, 6.9, 2.7% respectively. The formation of B<sub>12b</sub> under the same conditions was 19.3, 3.4, 1.3% and 27.8, 7.1, 2.8% respectively (Table 2). There is a good agreement between the % loss of B<sub>12</sub> and the % formation of B<sub>12b</sub>, indicating that artificial light (visible radiation) does not cause the formation of oxidation products. Thus sunlight (uv, visible and heat radiations) is more effective in degrading B<sub>12</sub> solutions and the formation of irreversible oxidation products might have resulted by the accompanied thermal reaction as observed in the photolysis of methylcobalamin (Pratt, 1964).

Table 1

Assay of cyanocobalamin and hydroxocobalamin in vitamin B<sub>12</sub> solutions exposed to sunlight\* (25°-28°C)

Vit. B <sub>12</sub> Concentration µg/ml	pH	Exposure time hours	Cyanocobalamin content***					Hydroxocobalamin (B <sub>12b</sub> ) µg/ml
			µg/ml B <sub>12</sub>	% initial concn.	% overall loss	% loss in terms of B <sub>12b</sub>	% loss in terms** of oxidation products	
950	4.0	2.0	750.7	79.0	21.0	15.2	5.8	144.9
95	4.0	2.0	17.5	18.5	81.5	78.9	2.6	75.0
950	5.5	2.0	799.8	84.2	15.8	8.9	6.9	84.8
95	5.5	2.0	29.3	30.8	69.2	67.9	1.3	64.5
950	7.0	2.0	810.2	85.3	14.7	8.7	6.0	82.7
95	7.0	2.0	41.5	43.7	56.3	55.2	1.1	52.4

\* Exposure to sunlight between 8 a.m. and 10 a.m. in the month of December.

\*\* Values obtained from % overall loss of B<sub>12</sub>- % loss in terms of B<sub>12b</sub>.

\*\*\* No change was observed in control samples stored in the dark for 2 hours.

Table 2

Assay of cyanocobalamin and hydroxocobalamin in vitamin B<sub>12</sub> solutions exposed to artificial light\* (25°-27°C)

Vit. B <sub>12</sub> Concentration µg/ml	pH	Exposure time hours	Cyanocobalamin content***					Hydroxocobalamin (B <sub>12b</sub> ) µg/ml
			µg/ml B <sub>12</sub>	% initial concn.	% overall loss	% loss in terms of B <sub>12b</sub>	% loss in terms** of oxidation products	
950	4.0	2.0	765.7	80.6	19.4	19.5	-	185.0
95	4.0	2.0	68.7	72.3	27.7	27.8	-	26.4
950	5.5	2.0	916.5	96.5	3.5	3.4	-	32.7
95	5.5	2.0	88.4	93.1	6.9	7.1	-	6.7
950	7.0	2.0	936.2	98.5	1.5	1.5	-	14.2
95	7.0	2.0	92.5	97.3	2.7	2.8	-	2.7

\* Philips HPLN 125 W high-pressure mercury vapour fluorescent lamp (emission at 405, 436, 545 and 577 nm); light intensity  $1.14 \pm 0.10 \times 10^{17}$  quanta  $s^{-1}$  determined by potassium ferrioxalate actinometry (Hatchard and Parker, 1956).

\*\* Values obtained from % overall loss of B<sub>12</sub> - % loss in terms of B<sub>12b</sub>.

\*\*\* No change was observed in control samples stored in the dark for 2 hours.

The aerobic photolysis of cyanocobalamin follows zero-order reaction (Vogler *et al.*, 1976; Ahmad *et al.*, 1992), in which the limiting factor is absorption of light. This is evident from the difference in the extent of photolysis (% loss) for 950 µg/ml and 95 µg/ml concentrations at all pH values under both the sunlight and artificial light and depends on the number of quanta absorbed to cause photochemical change in the solutions. Under the same quanta of light a dilute solution may degrade faster than the concentrated solution of the same species. This is an agreement with the observations of Baxter *et al.* (1953) for the photolysis of low and high potency cyanocobalmin injections.

The photodegradation of B<sub>12</sub> is greater at pH 4.0 compared to that at pH 7 as reported by Baxter et al. (1953). This appears to be due to greater susceptibility of the protonated form of B<sub>12</sub> i.e., the 5,6-dimethylbenzimidazole moiety (pK<sub>a</sub> 3.3, Hill et al., 1962), to photolysis than the neutral form of the molecule.

### REFERENCES

- Ahmad, I. and Hussain, W. (1992). Multicomponent spectrophotometric assay of cyanocobalamin, hydroxocobalamin and riboflavin. *Pakistan J. Pharm. Sci.*, **5**: 112-127.
- Ahmad, I. and Hussain W. (1993). Stability of cyanocobalamin in parenteral preparations. *Pakistan J. Pharm. Sci.*, **6**(1): (in press).
- Ahmad, I., Hussain, W. and Fareedi, A.A. (1992). Photolysis of cyanocobalamin in aqueous solution, *J. Pharm. Biomed Anal.*, **10**: 9-15.
- Anderson, N.H., Johnson, D., McLellan, M.A. and Munden, P. (1991). Photostability of drug substances and drug products in UK pharmaceutical laboratories, *J. Pharm. Biomed Anal.*, **6**: 443-449.
- Baxter, N., Horsford, J., Wokes, F., Norris, F.W. and Fernandes, S.J.G. (1953). Cyanocobalamin and hydroxocobalamin in vitamin B<sub>12</sub> injections, *J. Pharm. Pharmacol.* **5**: 723-736.
- British Pharmacopoeia (1988). Her Majesty's Stationary Office, London, p. 163.
- Brown, D.G. (1973). In: Current Research Topics in Bioinorganic Chemistry (Lippard, S.T., Ed.). Progress in Inorganic Chemistry, Vol. 18, Wiley, New York, pp 177-286.
- Connors, K.A., Amidon, G.L. and Stella, V.I. (1986). Chemical Stability of Pharmaceuticals, 2nd Edn., Wiley, New York, pp.377-384.
- DeMerre, L.J. and Wilson, C. (1956). Photolysis of vitamin B<sub>12</sub>. *J. Am. Pharm. Assoc., Sci. Ed.* **45**: 129-134.
- DeRitter, E. (1982). Vitamins in pharmaceutical formulations, *J. Pharm. Sci.*, **71**: 1073-1096.
- Hashmi, M.H. (1973). Assay of Vitamins in Pharmaceuticals Preparations. Wiley, New York, Chapter 2.
- Hatchard, C.G. and Parker, CA. (1956). A new sensitive chemical actinometer. II. Potassium ferrioxalate as a standard chemical actinometer, *Proc. Roy. Soc. (London)*, **A235**: 518-536.
- Hill, J.A., Pratt, J.M. and Williams, R.J.P. (1962). The corphyrins, *J. Theor. Biol.*, **3**: 423-445.
- Hogenkamp, H.P.C. (1975). In: Cobalamin, Biochemistry and Pathophysiology (Babor, B.M., Ed.), Wiley, New York, p.21.
- Kirschbaum (1981). In: Analytical Profiles of Drug Substances (Florey, K., Ed.), Vol. 10, Academic Press, New York, pp.183-288.
- Pratt, J.M. (1964). The Chemistry of Vitamin B<sub>12</sub>. Part II. Photochemical reactions, *J. Chem. Soc.*, 5154-5160.
- Pratt, J.M. (1972). Inorganic Chemistry of Vitamin B<sub>12</sub>. Academic Press, New York.
- United States Pharmacopoeia 22nd rev. (1990). United States Pharmacopoeial Convention, Inc., Rockville, MD, p.363.

- Veer, W.L.C., Edelhausen, J.H., Wijmenga, H.G. and Lens, J. (1950). Vitamin B<sub>12</sub>. I. The relation between vitamin B<sub>q12</sub> and B<sub>12b</sub>, *Biochim. Biophys. Acta*, **6**: 225-228.
- Vogler, A., Hirschman, R., Otto, H. and Kunkely, H. (1976). Photochemistry of biologically important transition metal complexes. I. Cyanocobalamin and related corrin complexes of rhodium (III), *Ber. Bunsenges Physik. Chem.*, **80**: 420-424.